Operating profit before amortization: Ocugen Inc (OCGN)
Ocugen, Inc. (OCGN) is developing gene therapy while awaiting FDA approval and the transition of its OCU400 drug into the final stage of trials. EBITDA cash flow confirms this potential, with the 0.00 level serving as a critical benchmark. However, manufacturing outsourcing creates a dependency on contractors, and the speculative nature of Phase 1/2 data expectations, coupled with current expenditures, increases investment risks.
%20Operating%20profit%20before%20deduction%20of%20amortization&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_OCGN_-_Ocugen-Inc._-_Operating-profit-before-deduction-of-amortization "OCGN (Ocugen Inc) Income before deduction of interest, taxes and amortization history from 11/23/2025 to 11/14/2026 | 👁️GURU.Markets👁️")
Ocugen (OCGN) - metric breakdowns and financial figures
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- company total debt and liquidity indicators:
- earnings and market ratios statistics:
OCGN - Net Profit|Projected Net Profit Ocugen, Inc.|OCGN - Price to Earnings Ratio|Price to Future Earnings Ratio ocugen.com|OCGN - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Ocugen|OCGN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Ocugen|OCGN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ocugen.com|OCGN - Earnings per share growth in current year|Expected net earnings per share growth next year Ocugen, Inc.
- sales revenue and business income indicators:
Fundamental company valuation:OCGN Ocugen Pharma
This metric reflects the net cash flow from core operations before depreciation and interest, allowing for an assessment of the business's internal efficiency without the influence of debt policy. By analyzing EBITDA volatility, an investor can see the real ability of Ocugen, Inc. (OCGN) to generate cash, which is currently limited due to geopolitical barriers and sanctions hindering international clinical trials of gene therapies.
Competitors of Ocugen, Inc. (OCGN)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS (ionispharma.com) - Operating profit before amortization|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|beamtx.com - Operating profit before amortization|Operating profit EBITDA SRPT (Sarepta)|TWST - Operating profit before deduction of amortization|TXG: Operating profit before deduction of amortization|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization biolifesolutions.com (BLFS)|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Operating profit EBITDA SION|Prime Medicine Bio (PRME) - Operating profit before depreciation charges|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|QURE: Operating profit before amortization|MeiraGTx - Operating profit EBITDA|RGNX (REGENXBIO Inc) - Operating profit before amortization|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PACB|BNTC (Benitec Biopharma Inc.) - Operating profit EBITDA|Operating profit EBITDA designtx.com|Profit before payment of interest, taxes and amortization Rocket Pharmaceuticals, Inc. (RCKT)|FDMT - Profit before interest, taxes and amortization|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|KRRO - Operating profit before deduction of amortization|EDIT: Operating profit before deduction of amortization|SLN - Operating profit EBITDA|PRQR: Operating profit EBITDA|Operating profit before depreciation charges Codexis CDXS|SGMO (Sangamo) - Operating profit EBITDA|Profit before interest, taxes and amortization Nautilus Biotechnology Inc NAUT|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Generation Bio - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BOLD|Exicure Corp - Operating profit EBITDA|Operating income before deduction of amortization Imunon, Inc. IMNN|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MBIO|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Bionano (BNGO)|Operating profit before deduction of amortization APDN (Applied DNA)|Operating income before deduction of amortization bluebird bio, Inc|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|omegatherapeutics.com (OMGA) - Profit before interest, taxes and amortization|Singular Genomics - Operating profit EBITDA|Regulus Therapeutics, Inc. (RGLS) - Operating profit before deduction of amortization|SYRS: Operating profit EBITDA|Operating profit before depreciation charges Telesis Bio, Inc TBIO|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
